Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

Part of paid clinical trials in Tampa, Florida.

Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Study ID
NCT00215995
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cisplatin — DRUG
    As outlined in Detailed Description
  • Irinotecan — DRUG
    As outlined in Detailed Description
  • ZD 1839 — DRUG
    As outlined in Detailed Description

Study Details

This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD 1839 following initial therapy with two other chemotherapy drugs, called Irinotecan (CPT-11) and Cisplatin.

Key Dates

Start date
Jul 31, 2003
Status verified
May 2007
Primary completion
May 31, 2007
Completion
May 31, 2007

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cisplatin, Irinotecan and ZD1839
    As outlined in Detailed Description.

Primary Outcome Measure

Number of Participants With Desired Response [ Time Frame: 48 Months ]

Locations (1)

FacilityCityStateZIPSite coordinators
H. Lee Moffitt Cancer Center & Research InstituteTampaFlorida33612-

Find similar trials in Tampa, FL

By condition
Esophageal cancerGastric cancer
By specialty
OncologyGI oncology
By research site
H. Lee Moffitt Cancer Center & Research Institute· Tampa, FL

Related Studies